Search
    • 1 min read

01/08/20 KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urine

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ -- KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its URO17™ Bladder Cancer Recurrence Test...more

20 views
    • 1 min read

11/03/19 Demonstration of Keratin 17 Biomarker for Urothelial Carcinoma Detection

Bladder carcinoma is a common urological cancer with high morbidity, mortality, and recurrence rates requiring frequent, invasive diagnostic procedures...more(1)more(2) 

11 views
    • 1 min read

10/08/19 A Better Future

A new biomarker allows effective, noninvasive screening of patients at risk of the disease. Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine professionals...more

2 views

Copyright © All Rights Reserved

LEGAL NOTICE; By accessing, browsing and/or otherwise using this website, you acknowledge that you have read, understood, and are bound by the KDx Diagnostics Inc. Website Terms and Conditions, and Privacy Policy and shall comply with all applicable laws and regulations. If you do not agree to these terms, do not use this website. Additionally, this website contains information on products that is targeted to many different audiences and may contain product details or information otherwise not accessible or valid in your country. Please be aware that KDx Diagnostics Inc. does not take any responsibility for your decision to access any such information on this website that may not comply with a legal process, regulation, registration or usage in the country of your origin.

​​

​